TOSCA is 1 of the 6 randomised, phase 3 clinical trials of the IDEA consortium, demonstrating non-inferiority of 3 months adjuvant chemotherapy as compared with 6 months chemotherapy in patients with stage III colon cancer [1]. However, a reduced benefit of adjuvant chemotherapy for patients over the age of 70 years is suggested.
Therefore, a subgroup analysis of TOSCA was performed [2]. Primary endpoint of this subgroup analysis was relapse-free interval (RFI), defined as time from randomisation to relapse or last disease evaluation. In TOSCA, 2,360 patients with stage III disease were enrolled: 1,667 aged <70 (‘younger patients’) and 693 aged ≥70 (‘elderly patients’). The elderly patients had an ECOG performance status more often equal to 1 compared with the younger patients (10% vs 3%), more T3/T4 tumours (91% vs 84%), and more tumours located on the right (49% vs 36%). More elderly patients had dose reductions (47% vs 41%) and prematurely interrupted the treatment (26% vs 19%).
In elderly patients, a higher proportion of recurrences was observed (24% vs 20%; P=0.033). However, the multivariable analysis of the RFI, corrected for sex, ECOG performance status, tumour site, stage, and grade, treatment, treatment duration, and dose reduction, did not indicate a statistically significant effect of age (HR 1.19; P=0.082). As such, different prognostic factors and possibly a reduced compliance may account for the observed difference in benefit of adjuvant chemotherapy between elderly and younger patients.
- Grothey A, N Engl J Med 2018;378:1177-1188.
- Rosati G, et al. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial. ESMO 2020 Virtual Meeting, abstract 399O.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer? Next Article
Surveillance after curative treatment for CRC »
« Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer? Next Article
Surveillance after curative treatment for CRC »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles

November 25, 2020
Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
November 25, 2020
Abiraterone in M1 hormone-naïve prostate cancer
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy